CA2349629C - Methods for the production of tcr gamma delta t cells - Google Patents

Methods for the production of tcr gamma delta t cells Download PDF

Info

Publication number
CA2349629C
CA2349629C CA2349629A CA2349629A CA2349629C CA 2349629 C CA2349629 C CA 2349629C CA 2349629 A CA2349629 A CA 2349629A CA 2349629 A CA2349629 A CA 2349629A CA 2349629 C CA2349629 C CA 2349629C
Authority
CA
Canada
Prior art keywords
cells
present
amount
culture medium
tcrys
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2349629A
Other languages
English (en)
French (fr)
Other versions
CA2349629A1 (en
Inventor
David Nicholson Bell
Danna Lynn Skea
Phyllis Robin Hedge
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Therapure Biopharma Inc
Original Assignee
Therapure Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Therapure Biopharma Inc filed Critical Therapure Biopharma Inc
Publication of CA2349629A1 publication Critical patent/CA2349629A1/en
Application granted granted Critical
Publication of CA2349629C publication Critical patent/CA2349629C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/59—Lectins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Compounds Of Unknown Constitution (AREA)
CA2349629A 1998-11-04 1999-11-04 Methods for the production of tcr gamma delta t cells Expired - Fee Related CA2349629C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10700698P 1998-11-04 1998-11-04
US60/107,006 1998-11-04
PCT/CA1999/001024 WO2000026347A1 (en) 1998-11-04 1999-11-04 Methods for the production of tcr gamma delta t cells

Publications (2)

Publication Number Publication Date
CA2349629A1 CA2349629A1 (en) 2000-05-11
CA2349629C true CA2349629C (en) 2010-01-26

Family

ID=22314363

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2349629A Expired - Fee Related CA2349629C (en) 1998-11-04 1999-11-04 Methods for the production of tcr gamma delta t cells

Country Status (10)

Country Link
US (1) US6537812B1 (https=)
EP (1) EP1127107B1 (https=)
JP (1) JP4435985B2 (https=)
AT (1) ATE421573T1 (https=)
AU (1) AU759373B2 (https=)
CA (1) CA2349629C (https=)
DE (1) DE69940352D1 (https=)
ES (1) ES2319942T3 (https=)
NZ (1) NZ511760A (https=)
WO (1) WO2000026347A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE449162T1 (de) * 2000-04-03 2009-12-15 Therapure Biopharma Inc Herstellung von tcr gamma delta t-zellen
US20030157060A1 (en) * 2000-04-03 2003-08-21 Bell David N Production of tcr gamma delta t cells
EP1778836B1 (en) * 2004-08-19 2010-08-04 University College Cardiff Consultants Limited Preparation of antigen-presenting human gamma delta t cells and use in immunotherapy
CN101313061B (zh) 2005-11-18 2013-05-15 大学健康网络 扩增双阴性t细胞的方法
CA2659697A1 (en) 2006-08-01 2008-02-07 Arigen Pharmaceuticals, Inc. Method of proliferating lak cell
GB201421716D0 (en) * 2014-12-05 2015-01-21 King S College London Cell expansion procedure
KR102663157B1 (ko) 2015-06-09 2024-05-13 감마델타 테라퓨틱스 엘티디 Ｔｃｒ감마 델타 양성 ｔ 세포의 생산 방법
AU2016274633B2 (en) * 2015-06-09 2022-04-21 Gammadelta Therapeutics Ltd Methods for the production of TCR gamma delta+ T cells
EP4148124A1 (en) 2015-10-30 2023-03-15 Cancer Research Technology Limited Expansion of non-haematopoietic tissue-resident gamma delta t cells and uses of these cells
GB201707048D0 (en) * 2017-05-03 2017-06-14 King S College London Expansion of gamma delta cells, compositions, and methods of use thereof
KR20210111746A (ko) * 2018-11-08 2021-09-13 감마델타 테라퓨틱스 리미티드 세포를 단리 및 증식하는 방법
EP4198120A4 (en) * 2020-08-14 2024-05-08 Shanghai Xinghua Bio Pharmaceutical Science & Technology Co., Ltd METHOD FOR PREPARING UNIVERSAL IMMUNE CELLS AND THEIR USE

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5639653A (en) * 1993-07-19 1997-06-17 Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva Universtiy Method for proliferating Vγ2Vδ2 T cells
US5877299A (en) * 1995-06-16 1999-03-02 Stemcell Technologies Inc. Methods for preparing enriched human hematopoietic cell preparations
CA2275141A1 (en) * 1996-10-29 1998-05-07 Thomas Spies Cell stress regulated human mhc class i gene
WO1998033891A1 (en) * 1997-01-31 1998-08-06 Hemosol Inc. Method for the production of selected lymphocytes
WO1999046365A1 (en) 1998-03-12 1999-09-16 Emory University Methods and compositions for the selective expansion of gamma/delta t-cells

Also Published As

Publication number Publication date
WO2000026347A1 (en) 2000-05-11
JP4435985B2 (ja) 2010-03-24
DE69940352D1 (de) 2009-03-12
CA2349629A1 (en) 2000-05-11
AU1021900A (en) 2000-05-22
AU759373B2 (en) 2003-04-10
ES2319942T3 (es) 2009-05-14
EP1127107B1 (en) 2009-01-21
US6537812B1 (en) 2003-03-25
NZ511760A (en) 2003-10-31
ATE421573T1 (de) 2009-02-15
JP2002528115A (ja) 2002-09-03
EP1127107A1 (en) 2001-08-29

Similar Documents

Publication Publication Date Title
US20250152630A1 (en) Methods for the production of tcr gamma delta + t cells
Dowell et al. Long-term proliferation of functional human NK cells, with conversion of CD56dim NK cells to a CD56bright phenotype, induced by carcinoma cells co-expressing 4-1BBL and IL-12
US12173319B2 (en) Methods for the production of TCR gamma delta + T cells
KR101867942B1 (ko) 바이러스 항원 특이적인 t 세포의 유도 및 증식 방법
CA2349629C (en) Methods for the production of tcr gamma delta t cells
Peragine et al. Immunophenotypic and functional characterization of ex vivo expanded natural killer cells for clinical use in acute lymphoblastic leukemia patients
EP1948788A1 (en) Method of expanding double negative t cells
EP1268746B1 (en) PRODUCTION OF TcR GAMMA DELTA T CELLS
AU2001248162A1 (en) Production of TcR gamma delta T cells
WO2004027052A1 (en) Th1 cell adoptive immunotherapy
Lehner et al. Functional characterization of monocyte-derived dendritic cells generated under serumfree culture conditions
US20030157060A1 (en) Production of tcr gamma delta t cells
Schilling et al. IRX-2, a novel biologic, favors the expansion of T effector over T regulatory cells in a human tumor microenvironment model
Ye et al. In vitro interactions between γδT cells, DC, and CD4+ T cells; implications for the immunotherapy of leukemia
HK40024937A (en) Methods for the production of tcr gamma delta+ t cells
Recktenwald CELLS RELEASED FROM THE IMMUNOAFFINITY DEVICE: NO RESIDUAL MOUSE IMMUNOGLOBULIN
HK1245831B (en) Methods for the production of tcr gamma delta+ t cells

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20171106